Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Background - The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2 July 2021
|
| In: |
Annals of oncology
Year: 2021, Jahrgang: 32, Heft: 10, Pages: 1245-1255 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2021.06.024 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2021.06.024 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753421021050 
|
| Verfasserangaben: | D. Miles, E. Ciruelos, A. Schneeweiss, F. Puglisi, T. Peretz-Yablonski, M. Campone, I. Bondarenko, Z. Nowecki, H. Errihani, S. Paluch-Shimon, A. Wardley, J.-L. Merot, P. Trask, Y. du Toit, C. Pena-Murillo, V. Revelant, D. Klingbiel & T. Bachelot, on behalf of the PERUSE investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1787761304 | ||
| 003 | DE-627 | ||
| 005 | 20230428005800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220129s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2021.06.024 |2 doi | |
| 035 | |a (DE-627)1787761304 | ||
| 035 | |a (DE-599)KXP1787761304 | ||
| 035 | |a (OCoLC)1341439597 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Miles, David W. |e VerfasserIn |0 (DE-588)1244965286 |0 (DE-627)1776049624 |4 aut | |
| 245 | 1 | 0 | |a Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication |c D. Miles, E. Ciruelos, A. Schneeweiss, F. Puglisi, T. Peretz-Yablonski, M. Campone, I. Bondarenko, Z. Nowecki, H. Errihani, S. Paluch-Shimon, A. Wardley, J.-L. Merot, P. Trask, Y. du Toit, C. Pena-Murillo, V. Revelant, D. Klingbiel & T. Bachelot, on behalf of the PERUSE investigators |
| 264 | 1 | |c 2 July 2021 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Collaborators: T. Bachelot, K. Bouzid, M. Campone, I. Desmoulins, B. Coudert, I. Bondarenko, Z. Nowecki, I. Glogowska, E. Ciruelos Gil, H. Errihani, F. Dalenc, F. Ricci, V. Dieras, B. Kaufman, S. Paluch-Shimon, A. Wardley, A. Schneeweiss und viele andere | ||
| 500 | |a Gesehen am 29.01.2022 | ||
| 520 | |a Background - The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. - Patients and methods - Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. - Results - Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade ≥3 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). - Conclusions - Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design. | ||
| 650 | 4 | |a HER2 positive | |
| 650 | 4 | |a hormone receptor | |
| 650 | 4 | |a metastatic breast cancer | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a paclitaxel | |
| 650 | 4 | |a pertuzumab | |
| 700 | 1 | |a Ciruelos, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Puglisi, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peretz-Yablonski, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Campone, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bondarenko, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nowecki, Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Errihani, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paluch-Shimon, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wardley, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Merot, J. -L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trask, P. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 32(2021), 10 vom: Okt., Seite 1245-1255 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:10 |g month:10 |g pages:1245-1255 |g extent:11 |a Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2021.06.024 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753421021050 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220129 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1787761304 |e 4048028847 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"2 July 2021"}],"relHost":[{"recId":"320428796","origin":[{"dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990"}],"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2003498-2"],"issn":["1569-8041"],"eki":["320428796"]},"pubHistory":["1.1990 -"],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"language":["eng"],"part":{"text":"32(2021), 10 vom: Okt., Seite 1245-1255","extent":"11","pages":"1245-1255","issue":"10","volume":"32","year":"2021"},"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationAnnals of oncology"}],"id":{"doi":["10.1016/j.annonc.2021.06.024"],"eki":["1787761304"]},"physDesc":[{"extent":"11 S."}],"title":[{"title":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication","title_sort":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Collaborators: T. Bachelot, K. Bouzid, M. Campone, I. Desmoulins, B. Coudert, I. Bondarenko, Z. Nowecki, I. Glogowska, E. Ciruelos Gil, H. Errihani, F. Dalenc, F. Ricci, V. Dieras, B. Kaufman, S. Paluch-Shimon, A. Wardley, A. Schneeweiss und viele andere","Gesehen am 29.01.2022"],"person":[{"role":"aut","family":"Miles","display":"Miles, David W.","given":"David W."},{"family":"Ciruelos","role":"aut","display":"Ciruelos, E.","given":"E."},{"family":"Schneeweiss","role":"aut","given":"Andreas","display":"Schneeweiss, Andreas"},{"display":"Puglisi, F.","given":"F.","family":"Puglisi","role":"aut"},{"role":"aut","family":"Peretz-Yablonski","given":"T.","display":"Peretz-Yablonski, T."},{"role":"aut","family":"Campone","display":"Campone, M.","given":"M."},{"given":"I.","display":"Bondarenko, I.","family":"Bondarenko","role":"aut"},{"family":"Nowecki","role":"aut","display":"Nowecki, Z.","given":"Z."},{"role":"aut","family":"Errihani","given":"H.","display":"Errihani, H."},{"role":"aut","family":"Paluch-Shimon","given":"S.","display":"Paluch-Shimon, S."},{"given":"A.","display":"Wardley, A.","role":"aut","family":"Wardley"},{"given":"J. -L.","display":"Merot, J. -L.","role":"aut","family":"Merot"},{"role":"aut","family":"Trask","given":"P.","display":"Trask, P."}],"recId":"1787761304","name":{"displayForm":["D. Miles, E. Ciruelos, A. Schneeweiss, F. Puglisi, T. Peretz-Yablonski, M. Campone, I. Bondarenko, Z. Nowecki, H. Errihani, S. Paluch-Shimon, A. Wardley, J.-L. Merot, P. Trask, Y. du Toit, C. Pena-Murillo, V. Revelant, D. Klingbiel & T. Bachelot, on behalf of the PERUSE investigators"]},"language":["eng"]} | ||
| SRT | |a MILESDAVIDFINALRESUL2202 | ||